Xbrane ‘shifts focus’ to biosimilar portfolio

Xbrane Biopharma has announced that it is shifting its full strategic focus to its biosimilars pipeline in the wake of striking a global co-development deal with Stada for its Xlucane (ranibizumab) rival to Lucentis. The strategic shift means that the Swedish firm will abandon, at least for the time being, development efforts on generic long-acting injectables beyond its existing Spherotide (triptorelin) product.